Grégoire B Morand1, Nanina Anderegg2, Domenic Vital1, Kristian Ikenberg3, Gerhard F Huber1, Michael B Soyka1, Matthias Egger2, David Holzmann4. 1. Department for Otorhinolaryngology - Head and Neck Surgery, University Hospital and University of Zurich, Switzerland. 2. Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland. 3. Department of Surgical Pathology, University Hospital Zurich, Switzerland. 4. Department for Otorhinolaryngology - Head and Neck Surgery, University Hospital and University of Zurich, Switzerland. Electronic address: david.holzmann@usz.ch.
Abstract
OBJECTIVE: Sinonasal undifferentiated carcinoma (SNUC) is an aggressive malignancy first described by Frierson et al. in 1986. As the tumor is very rare, current treatment recommendations are based on institutional case reports. We thus felt the need to perform a comprehensive systematic review and meta-analysis to investigate how treatment modalities are associated with survival. DESIGN: Case-series, systematic review and meta-analysis METHODS: We searched the OvidMedline, OvidEmbase, Web of Science, Biosis, Scopus and the Cochrane Library database libraries. We extracted aggregate and individual patient data for statistical analysis. To study the association between treatment modalities and survival, we used random-effects meta-regression for the aggregate- and cox mixed-effects models. RESULTS: 379 citations were found; 29 case series could be included in the final analysis, including a total number of 390 single patients (34.6% female). Median age at diagnosis was 52 years. 80.9% of patients presented with a T4 tumor and 16.0% with nodal metastasis at diagnosis. In individual patient data (IPD) meta-analysis, single modality (surgery alone or radiation alone) treatment was associated with reduced survival compared to double modality (surgery & radiation or chemoradiation) treatment (adjusted Hazard Ratio [aHR] 2.97, 95% ConfidenceInterval [1.41-6.27]) and compared to triple modality (surgery & radiation & chemotherapy) treatment (aHR 2.80 95%-CI 1.29-6.05 for triple vs. single modality). Triple modality treatment was not superior to double modality treatment. (aHR 1.06, 95%-CI 0.59-1.92). CONCLUSION: Double and triple modality treatment are associated with improved survival over single modality but there is no evidence that triple modality is superior to double modality treatment.
OBJECTIVE:Sinonasal undifferentiated carcinoma (SNUC) is an aggressive malignancy first described by Frierson et al. in 1986. As the tumor is very rare, current treatment recommendations are based on institutional case reports. We thus felt the need to perform a comprehensive systematic review and meta-analysis to investigate how treatment modalities are associated with survival. DESIGN: Case-series, systematic review and meta-analysis METHODS: We searched the OvidMedline, OvidEmbase, Web of Science, Biosis, Scopus and the Cochrane Library database libraries. We extracted aggregate and individual patient data for statistical analysis. To study the association between treatment modalities and survival, we used random-effects meta-regression for the aggregate- and cox mixed-effects models. RESULTS: 379 citations were found; 29 case series could be included in the final analysis, including a total number of 390 single patients (34.6% female). Median age at diagnosis was 52 years. 80.9% of patients presented with a T4 tumor and 16.0% with nodal metastasis at diagnosis. In individual patient data (IPD) meta-analysis, single modality (surgery alone or radiation alone) treatment was associated with reduced survival compared to double modality (surgery & radiation or chemoradiation) treatment (adjusted Hazard Ratio [aHR] 2.97, 95% ConfidenceInterval [1.41-6.27]) and compared to triple modality (surgery & radiation & chemotherapy) treatment (aHR 2.80 95%-CI 1.29-6.05 for triple vs. single modality). Triple modality treatment was not superior to double modality treatment. (aHR 1.06, 95%-CI 0.59-1.92). CONCLUSION: Double and triple modality treatment are associated with improved survival over single modality but there is no evidence that triple modality is superior to double modality treatment.
Authors: Vittorio D'Aguanno; Massimo Ralli; Bruna Cerbelli; Antonio Greco; Marco De Vincentiis Journal: Oncol Lett Date: 2019-04-15 Impact factor: 2.967
Authors: Moran Amit; Ahmed S Abdelmeguid; Teemaranawich Watcherporn; Hideaki Takahashi; Samantha Tam; Diana Bell; Renata Ferrarotto; Bonnie Glisson; Michael E Kupferman; Dianna B Roberts; Shirley Y Su; Shaan M Raza; Franco DeMonte; Ehab Y Hanna Journal: J Clin Oncol Date: 2019-01-07 Impact factor: 44.544
Authors: Molly E Heft Neal; Andrew C Birkeland; Apurva D Bhangale; Jingyi Zhai; Aditi Kulkarni; Susan K Foltin; Brittany M Jewell; Megan L Ludwig; Lisa Pinatti; Hui Jiang; Jonathan B McHugh; Lawence Marentette; Erin L McKean; J Chad Brenner Journal: BMC Cancer Date: 2021-05-29 Impact factor: 4.430
Authors: Muhammad Faisal; Rudolf Seemann; Claudia Lill; Sasan Hamzavi; Arno Wutzl; Boban M Erovic; Stefan Janik Journal: Head Neck Date: 2020-01-10 Impact factor: 3.147
Authors: Christian M Meerwein; Panagiotis Balermpas; Domenic G Vital; Martina A Broglie; Michael B Soyka; David Holzmann Journal: Am J Rhinol Allergy Date: 2021-07-22 Impact factor: 2.467